Merck starts ENHANCE 3 COPD trial as cancer drug review nears
Yahoo Finance Singapore reports that Merck has started a COPD trial named ENHANCE 3, at a time when a review of one of its cancer drugs is approaching.
Merck (MRK) has started a trial called ENHANCE 3 in chronic obstructive pulmonary disease (COPD), according to a news item published by Yahoo Finance Singapore on 9 November 2026.
The item's headline also says that a review of a Merck cancer drug is approaching. The text available to LungDaily does not name the drug, the regulator or the expected timing of the review.
The source text does not give further details of ENHANCE 3, including the treatment being tested, the trial design, the number of participants or the endpoints. LungDaily will update this report if more information is published.
